Researchers investigated the role of the CD98 glycoprotein in inducing an inflammatory response to SARS-CoV-2 in patients of progressive fibrosis interstitial lung diseases, including the archetypal PFILD, idiopathic pulmonary fibrosis.
The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity